STRYKER CORPSS

STRYKER CORP

7,443.22MXND
+70.22+0.95%
At close at Mar 21, 14:58 GMT
MXN
No trades
See on Supercharts

SYK fundamentals

Key facts

Market capitalization‪2.87 T‬MXN
Founded1941
Employees (FY)‪53 K‬
CEOKevin A. Lobo
About

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Ownership
‪‪381.58 M‬‬
Free Float shares
‪‪356.95 M‬‬ (93.55%)
Closely held shares
‪‪24.63 M‬‬ (6.45%)
Free Float shares
‪‪356.95 M‬‬ (93.55%)
Closely held shares
‪‪24.63 M‬‬ (6.45%)
Capital structure
Market cap
‪‪2.87 T‬‬
Debt
‪‪294.39 B‬‬
Cash & equivalents
‪‪93.68 B‬‬
Enterprise value
‪‪3.07 T‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪2.87 T‬‬
Price to earning ratio (P/E)
46.88x
Price to sales ratio (P/S)
6.22x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
46.88x
Price to sales ratio (P/S)
6.22x
Valuation ratios
‪0.00‬
‪1.70‬
‪3.40‬
‪5.10‬
‪6.80‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪12.00‬
‪24.00‬
‪36.00‬
‪48.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪8%‬
‪11%‬
‪14%‬
‪17%‬
‪20%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪35.00 B‬‬
‪‪70.00 B‬‬
‪‪105.00 B‬‬
‪‪140.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪35.00 B‬‬
‪‪70.00 B‬‬
‪‪105.00 B‬‬
‪‪140.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪35.00 B‬‬
‪‪70.00 B‬‬
‪‪105.00 B‬‬
‪‪140.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
MedSurg and Neurotechnology
Orthopaedics
By country
Period: 2024
United States
Europe, Middle East, Africa
Asia Pacific
Other Countries

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪35.00 B‬‬
‪‪70.00 B‬‬
‪‪105.00 B‬‬
‪‪140.00 B‬‬
Actual
Estimate
Earnings
Next:Apr 30, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪21.00‬
‪42.00‬
‪63.00‬
‪84.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
41.73%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
0.87%
Next payment
17.014
Next ex-date
Mar 31, 2025
Dividend history
‪0.85%‬
‪0.93%‬
‪1.01%‬
‪1.09%‬
‪1.17%‬
2020
2021
2022
2023
2024
‪0.00‬
‪17.00‬
‪34.00‬
‪51.00‬
‪68.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪80.00 B‬‬
‪‪160.00 B‬‬
‪‪240.00 B‬‬
‪‪320.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪150.00 B‬‬
‪‪300.00 B‬‬
‪‪450.00 B‬‬
‪‪600.00 B‬‬
Assets
Liabilities